Gilead CEO: M&A is top of mind for us this year

John Milligan, Gilead president and CEO, speaks to CNBC's Meg Tirrell about potential M&A, drug-pricing pressure under President-elect Donald Trump and the company's hepatitis C drugs.
06:00
Tue, Jan 10 20175:07 PM EST